iTeos Therapeutics (ITOS)
(Delayed Data from NSDQ)
$11.27 USD
+0.05 (0.45%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $11.26 -0.01 (-0.09%) 4:38 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Cash flow Statements
Fiscal Year End for iTeos Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -112.64 | 96.65 | 214.52 | -38.03 | -22.45 |
Depreciation/Amortization & Depletion | -9.34 | -0.93 | 0.60 | 0.54 | 0.61 |
Net Change from Assets/Liabilities | -8.80 | -228.48 | 284.22 | 9.33 | -1.08 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 27.02 | 21.56 | 13.79 | 2.99 | -0.22 |
Net Cash From Operating Activities | -103.76 | -111.19 | 513.14 | -25.18 | -23.15 |
Property & Equipment | -2.97 | -0.94 | -1.18 | -0.36 | -0.72 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 75.62 | -445.12 | -0.06 | -0.02 | -0.21 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 72.66 | -446.06 | -1.24 | -0.38 | -0.93 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 1.11 | 0.93 | 2.94 | 122.63 | 22.47 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 1.06 | 0.72 | 4.05 | 0.07 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 213.66 | 0.00 |
Net Cash from Financing Activities | 1.11 | 1.98 | 3.66 | 340.34 | 22.54 |
Effect of Exchange Rate Changes | -3.60 | -8.53 | -3.18 | 1.68 | -0.53 |
Net Change In Cash & Equivalents | -33.59 | -563.80 | 512.38 | 316.46 | -2.06 |
Cash at Beginning of Period | 285.04 | 848.84 | 336.45 | 19.99 | 22.05 |
Cash at End of Period | 251.45 | 285.04 | 848.84 | 336.45 | 19.99 |
Diluted Net EPS | -3.15 | 2.56 | 5.68 | -2.88 | -130.85 |
Fiscal Year End for iTeos Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -45.34 | -38.22 | -112.64 | -82.09 | -49.85 |
Depreciation/Amortization & Depletion | -4.91 | 0.30 | -9.34 | 0.67 | 0.45 |
Net Change from Assets/Liabilities | -31.40 | 0.99 | -8.80 | -20.36 | -14.08 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 15.33 | 4.52 | 27.02 | 11.79 | 7.39 |
Net Cash From Operating Activities | -66.33 | -32.40 | -103.76 | -89.99 | -56.10 |
Property & Equipment | 0.00 | -0.95 | -2.97 | -1.57 | -0.82 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -53.28 | -68.66 | 75.62 | 12.67 | -10.77 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -53.28 | -69.60 | 72.66 | 11.10 | -11.59 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 122.40 | 0.02 | 1.11 | 0.81 | 0.80 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 122.40 | 0.02 | 1.11 | 0.81 | 0.80 |
Effect of Exchange Rate Changes | -2.84 | -2.55 | -3.60 | -2.55 | -1.66 |
Net Change In Cash & Equivalents | -0.05 | -104.53 | -33.59 | -80.64 | -68.56 |
Cash at Beginning of Period | 251.45 | 251.45 | 285.04 | 285.04 | 285.04 |
Cash at End of Period | 251.40 | 146.92 | 251.45 | 204.40 | 216.48 |
Diluted Net EPS | -0.18 | -1.07 | -0.85 | -0.90 | -0.96 |